Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series

The study reported on the effectiveness of oral tofacitinib in 32 Korean patients with moderate-to-severe alopecia areata who had not responded to other treatments. It found that 75% of the patients saw hair regrowth, with 56.3% achieving 50% hair regrowth within 3 months and 28.1% achieving 90% hair regrowth within 6 months. Tofacitinib was well tolerated without serious side effects. The study concluded that tofacitinib is effective and safe for treating refractory moderate-to-severe alopecia areata in Korean patients, although ongoing treatment is necessary to maintain results. Further studies were recommended to determine the optimal dosage and treatment duration.